Recent company announcements on PROSTVAC®
15 November 2011 Bavarian Nordic Initiates Pivotal Phase 3 Trial of PROSTVAC® Prostate Cancer Immunotherapy
01 June 2011 Bavarian Nordic Announces Presentation of PROSTVAC® Data at the 2011 ASCO Annual Meeting
28 February 2011 Bavarian Nordic Announces Start of Randomized Phase 2 Study Comparing PROSTVAC® and Chemotherapy versus Chemotherapy
8 December 2010 Bavarian Nordic Receives Special Protocol Assessment Agreement from the FDA for Phase 3 Trial of PROSTVAC®®
29 April 2010 Bavarian Nordic Receives FDA Fast Track Designation for PROSTVAC™
9 March 2010 Bavarian Nordic Successfully Completes End of Phase II Meeting for PROSTVAC™
26 January 2010 PROSTVAC™ paper published in Journal of Clinical Oncology
21 September 2009 New and interesting PROSTVAC™ data indicate broad therapeutic use in metastatic prostate cancer
01 July 2009 New Review on PROSTVAC™ published by key Investigators from NCI
30 May 2009 PROSTVAC™ data presented at the ASCO Meeting demonstrates the potential for significant increases in life expectancy in late-stage prostate cancer
16 April 2009 PROSTVAC™ data accepted for an oral presentation at the ASCO Annual Meeting
25 February 2009 Bavarian Nordic reports further data on PROSTVAC™
